FDA’s Corrupt Peptides Policy Endangers Public Health
WASHINGTON, D.C. – The U.S. Food and Drug Administration (FDA) has abdicated its responsibility to stop the illicit peptides trade and instead allowed it to flourish, according to a new report from Public Citizen. The FDA has the authority to halt the marketing and sale of unapproved drugs, but sales of unapproved peptides have boomed over the last two years in large part because the FDA looked the other way as hundreds of companies, many of them based in China, sold them to U.S. consumers.
“Although the new HHS policy gambles with public health, there is one clear set of winners: MAHA movement leaders who have financial stakes in peptide sales or contributed to the MAHA political action committee,” said Peter Whoriskey, a research director for Public Citizen and author of the report. “By looking the other way on unapproved peptides, the FDA has established a dangerous precedent, abdicated its public-health responsibilities, and put Americans at risk.”
In October 2026, U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. announced that the government would no longer enforce rules barring pharmacies from selling six peptides popular in health and wellness circles. The six injectable peptides are touted as ways to help repair muscles and tendons, improve gut health, or extend life. None have been approved as a drug by the FDA, however, and government scientists previously reported that they pose “significant safety risks.” The market has grown to hundreds of peptide vendors, and has matured enough that companies have sprung up to test peptides for purity and publish the results.
Since the beginning of the second Trump administration, the FDA has issued more than 150 warning letters to companies marketing unapproved substances. Only one went to a vendor selling one of the six unapproved health and wellness peptides, and that company had already agreed to shut down for unrelated reasons. In at least 11 cases, the FDA investigated and sent warnings to companies selling unauthorized GLP-1 weight-loss drugs. Those same 11 companies were also selling at least one of the six peptides, but the warning letters did not mention those sales.